Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Kavar Capital Partners Group LLC

Kavar Capital Partners Group LLC decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 28,915 shares of the medical research company’s stock after selling 464 shares during the quarter. Thermo Fisher Scientific accounts for about 2.8% of Kavar Capital Partners Group LLC’s portfolio, making the stock its 7th largest holding. Kavar Capital Partners Group LLC’s holdings in Thermo Fisher Scientific were worth $17,886,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of TMO. Vicus Capital bought a new position in Thermo Fisher Scientific in the 1st quarter valued at about $451,000. Symphony Financial Ltd. Co. bought a new position in Thermo Fisher Scientific in the 1st quarter valued at about $259,000. Founders Financial Securities LLC grew its holdings in shares of Thermo Fisher Scientific by 3.5% during the 1st quarter. Founders Financial Securities LLC now owns 2,039 shares of the medical research company’s stock valued at $1,185,000 after purchasing an additional 69 shares during the last quarter. Cornerstone Wealth Group LLC grew its holdings in shares of Thermo Fisher Scientific by 109.4% during the 1st quarter. Cornerstone Wealth Group LLC now owns 932 shares of the medical research company’s stock valued at $542,000 after purchasing an additional 487 shares during the last quarter. Finally, Trilogy Capital Inc. grew its holdings in shares of Thermo Fisher Scientific by 12.8% during the 1st quarter. Trilogy Capital Inc. now owns 502 shares of the medical research company’s stock valued at $292,000 after purchasing an additional 57 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 6,300 shares of the stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $602.09, for a total transaction of $3,793,167.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,548,375.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 6,300 shares of the stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $602.09, for a total transaction of $3,793,167.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,548,375.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $76,420,473.36. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TMO shares. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, September 20th. Bernstein Bank boosted their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research report on Tuesday, October 22nd. Redburn Atlantic started coverage on shares of Thermo Fisher Scientific in a research note on Monday, October 14th. They set a “buy” rating and a $680.00 price target for the company. Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Sanford C. Bernstein decreased their price target on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating for the company in a research note on Thursday. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $649.33.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $554.38 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. The firm’s 50-day simple moving average is $605.12 and its two-hundred day simple moving average is $584.00. The company has a market cap of $211.77 billion, a PE ratio of 34.39, a price-to-earnings-growth ratio of 3.75 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $420.21 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. During the same period in the prior year, the business earned $5.69 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up .2% compared to the same quarter last year. Research analysts predict that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.